哌啶,1-(3-碘苯甲酰)- | 121114-31-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 哌啶,1-(3-碘苯甲酰)-
• 英文名称: N-(3-iodobenzoyl)piperidine
• 英文别名: Piperidine, 1-(3-iodobenzoyl)-；(3-iodophenyl)-piperidin-1-ylmethanone
• CAS: 121114-31-6
• 化学式: C₁₂H₁₄INO
• mdl: MFCD00638921
• 分子量: 315.154
• InChiKey: VZBNRYSPDWCBGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  哌啶,1-(3-碘苯甲酰)- 、 6,8-dimethoxyisoquinolin-1(2H)-one 在 copper(l) iodide 、 potassium carbonate 、 L-脯氨酸 作用下， 以 二甲基亚砜 为溶剂， 反应 24.0h， 以47%的产率得到6,8-dimethoxy-2-(3-(piperidin-1-ylcarbonyl)phenyl) isoquinoline-1(2H)-one
  参考文献：
  名称：

  Discovery of 2-aryl-8-hydroxy (or methoxy)-isoquinolin-1(2H)-ones as novel EGFR inhibitor by scaffold hopping

  摘要：

  2-Aryl-8-hydroxy (or methoxy)-isoquinolin-1(2H)-one has been proposed as a novel scaffold of EGFR inhibitor based on scaffold hoping. In the present study, a series of 2-aryl-8-hydroxy (or methoxy)-isoquinolin-1(2H)-one derivatives were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against two human cancer cell lines, including A431 and A549. The SAR of the title compounds was preliminarily discussed. The compounds with ideal inhibition were evaluated through ELISA-based EGFR-TK assay. Compound 6c showed the best activity against A431 and EGFR tyrosine kinase. These findings suggest that title compounds are EGFR inhibitors with novel structures. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.09.027

文献信息

• [EN] MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS<br/>[FR] COMPOSÉS DE MORPHOLINONE EN TANT QU'INHIBITEURS DE FACTEUR IXA
  申请人：MOCHIDA PHARM CO LTD

  公开号：WO2010065717A1

  公开（公告）日：2010-06-10

  The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

  本发明提供了如下描述的化合物I的化合物，或其药用可接受的盐或溶剂。本发明还提供包含一个或多个所述化合物的药物组合物，以及使用所述化合物治疗或预防血栓、栓塞、高凝血性或纤维变化的方法。
• Catalytic Enantioselective Alkylation and Arylation of Aldehydes by Using Grignard Reagents
  作者：Yusuke Muramatsu、Shinichi Kanehira、Masato Tanigawa、Yuta Miyawaki、Toshiro Harada

  DOI：10.1246/bcsj.20090232

  日期：2010.1.15

  the resulting mixed titanium reagents undergo addition to aldehydes with high enantioselectivities (typically >90% ee) and high yields. The method is applicable to various combination of aldehydes (R 1 CHO; R 1 = aryl, heteroaryl, 1-alkenyl, and alkyl) and Grignard reagents (R 2 MgX; R 2 = primary alkyl and aryl). Thus, a variety of enantiomerically enriched secondary alcohols (R 1 CH*(OH)R 2 ) can

  我们开发了一种有效且实用的方法，通过使用格氏试剂与四异丙醇钛的组合，对醛进行催化对映选择性烷基化和芳基化。格氏试剂和四异丙醇钛以约 1 的摩尔比混合。1:2。在由 BINOL 配体 4a 和 4b 以及四异丙醇钛原位形成的催化剂（2-4 mol%）存在下，所得混合钛试剂以高对映选择性（通常 >90% ee）和高产量。该方法适用于醛（R 1 CHO；R 1 = 芳基、杂芳基、1-烯基和烷基）和格氏试剂（R 2 MgX；R 2 = 伯烷基和芳基）的各种组合。因此，可以制备多种对映体富集的仲醇(R 1 CH*(OH)R 2 )。也已经证明可以使用官能化的芳基格氏试剂来生成高度官能化的二芳基甲醇。该方法的制备效用已通过以下事实表明：反应操作简单，可以毫无困难地在 10 毫摩尔规模上进行，并且配体可以很容易地回收。
• MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS
  申请人：Nishida Hidemitsu

  公开号：US20110059958A1

  公开（公告）日：2011-03-10

  The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

  本发明提供了如下式（I）所描述的化合物，或其药学上可接受的盐或溶剂。本发明还提供了包含一种或多种所述化合物的制药组合物，并使用该化合物治疗或预防血栓、栓塞、高凝状态或纤维化变化的方法。
• Catalytic Asymmetric Aryl Transfer Reactions to Aldehydes with Grignard Reagents as the Aryl Source
  作者：Yusuke Muramatsu、Toshiro Harada

  DOI：10.1002/chem.200801612

  日期：——
• US8642582B2
  申请人：——

  公开号：US8642582B2

  公开（公告）日：2014-02-04